Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder

2002625 citationsJournal Article

Authors

John M. Kane · Zucker Hillside Hospital

William H. Carson · Bristol-Myers Squibb (United States)

Anutosh Ranjan Saha · Otsuka (United States)

Robert D. McQuade · Bristol-Myers Squibb (Germany)

Г. Ингенито · Otsuka (United States)

Dan Zimbroff · Pacific Clinical Research

Mirza W. Ali

Abstract

Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.

Topics & Keywords

Schizophrenia research and treatment Bipolar Disorder and Treatment Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Psychiatry

Volume 63, Issue 9, pp. 763-771

DOI: 10.4088/jcp.v63n0903

Field-Weighted Citation Impact: 26.72